CN109432182A - A kind of Chinese medicine composition that treating nephrosis, enema fluid and preparation method thereof - Google Patents
A kind of Chinese medicine composition that treating nephrosis, enema fluid and preparation method thereof Download PDFInfo
- Publication number
- CN109432182A CN109432182A CN201910044647.7A CN201910044647A CN109432182A CN 109432182 A CN109432182 A CN 109432182A CN 201910044647 A CN201910044647 A CN 201910044647A CN 109432182 A CN109432182 A CN 109432182A
- Authority
- CN
- China
- Prior art keywords
- parts
- radix
- chinese medicine
- preparation
- dandelion
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/02—Medicinal preparations containing materials or reaction products thereof with undetermined constitution from inanimate materials
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/56—Materials from animals other than mammals
- A61K35/618—Molluscs, e.g. fresh-water molluscs, oysters, clams, squids, octopus, cuttlefish, snails or slugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/06—Fungi, e.g. yeasts
- A61K36/07—Basidiomycota, e.g. Cryptococcus
- A61K36/074—Ganoderma
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/23—Apiaceae or Umbelliferae (Carrot family), e.g. dill, chervil, coriander or cumin
- A61K36/232—Angelica
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/28—Asteraceae or Compositae (Aster or Sunflower family), e.g. chamomile, feverfew, yarrow or echinacea
- A61K36/286—Carthamus (distaff thistle)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/28—Asteraceae or Compositae (Aster or Sunflower family), e.g. chamomile, feverfew, yarrow or echinacea
- A61K36/288—Taraxacum (dandelion)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/29—Berberidaceae (Barberry family), e.g. barberry, cohosh or mayapple
- A61K36/296—Epimedium
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/34—Campanulaceae (Bellflower family)
- A61K36/344—Codonopsis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/48—Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
- A61K36/481—Astragalus (milkvetch)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/53—Lamiaceae or Labiatae (Mint family), e.g. thyme, rosemary or lavender
- A61K36/537—Salvia (sage)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/70—Polygonaceae (Buckwheat family), e.g. spineflower or dock
- A61K36/708—Rheum (rhubarb)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0031—Rectum, anus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/33—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones
- A61K2236/331—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones using water, e.g. cold water, infusion, tea, steam distillation, decoction
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/50—Methods involving additional extraction steps
- A61K2236/55—Liquid-liquid separation; Phase separation
Abstract
The present invention provides a kind of Chinese medicine compositions for treating nephrosis, enema fluid and preparation method thereof, belong to technical field of Chinese medicine.Chinese medicine composition of the present invention includes the component of following mass parts: 5~35 parts of rheum officinale, 20~45 parts of Radix Astragali, 20~40 parts of longspur epimedium, 20~45 parts of Radix Angelicae Sinensis, 10~35 parts of Radix Salviae Miltiorrhizae, 5~20 parts of Radix Codonopsis, 5~15 parts of safflower, 10~30 parts of Concha Ostreae, 20~40 parts of dandelion, 5~15 parts of ganoderma lucidum.The Chinese medicine composition is using rheum officinale as monarch drug in a prescription, logical internal organs rushes down turbid, activating microcirculation and removing stasis medicinal, safflower, Radix Angelicae Sinensis, Radix Salviae Miltiorrhizae blood circulation promoting nourishes blood, Radix Codonopsis, Radix Astragali, ganoderma lucidum Bu Qi Fu Zheng are with metaplasia qi and blood, Herba Epimedii kidney-replenishing, dandelion hardship is let out with opening, dampness removing dissipating bind, Concha Ostreae astringency inducing, it prevents rheum officinale from unloading wound, is the medicine of tying-in.5 strengthening vital QI to eliminate pathogenic factors of complete square compatibility, attacks benefit dual-purpose, thus the effect of reaching turbid nourishing qi and blood, toxin expelling drop, activating microcirculation and removing stasis medicinal.Clinical treatment effective percentage is 85% or more.
Description
Technical field
The invention belongs to technical field of Chinese medicine, and in particular to a kind of Chinese medicine composition for treating nephrosis, enema fluid and its
Preparation method.
Background technique
Nephrosis is a kind of disease for being primary in kidney or influencing kidney secondary to other organs lesion, clinical manifestation
Mainly albuminuria, blood urine, oedema, hypertension etc..If disease progression, the nephron that also will cause is badly damaged, glomerulus filter
The decline of rate progressive is crossed, body excretion metabolism waste is made and adjusts Water-Electrolyte, disturbance of acid-base balance, and then developing is chronic renal
Popular name for.Modern medicine is mainly haemodialysis and kidney transplant etc. to effective treatment of terminal phase chronic kidney disease, but it cannot
For treating early metaphase chronic kidney disease, and somewhat expensive, it has also become the heavy burden of patient home.Research confirms that albuminuria is
Accelerate the independent hazard factor of nephrosis process.Therefore, urgent clinical needs exploitation Small side effects and low-cost new drug occur.
Summary of the invention
It is the problem of in view of background technique, low in cost the purpose of the present invention is to provide a kind of Small side effects,
Treat the good Chinese medicine composition of nephrosis effect, enema fluid and preparation method thereof.
The present invention provides a kind of Chinese medicine composition, the composition includes the component of following mass parts: rheum officinale 5~35
Part, 20~45 parts of Radix Astragali, 20~40 parts of longspur epimedium, 20~45 parts of Radix Angelicae Sinensis, 10~35 parts of Radix Salviae Miltiorrhizae, 5~20 parts of Radix Codonopsis, safflower 5~
15 parts, 10~30 parts of Concha Ostreae, 20~40 parts and 5~15 parts of ganoderma lucidum of dandelion.
Preferably, the Chinese medicine composition includes the component of following mass parts: 20~32 parts of rheum officinale, 30~42 parts of Radix Astragali,
25~35 parts of longspur epimedium, 30~42 parts of Radix Angelicae Sinensis, 20~32 parts of Radix Salviae Miltiorrhizae, 8~15 parts of Radix Codonopsis, 8~12 parts of safflower, Concha Ostreae 15~25
Part, 25~35 parts and 8~12 parts of ganoderma lucidum of dandelion.
It is further preferred that the Chinese medicine composition includes the component of following mass parts: 30 parts of rheum officinale, 40 parts of Radix Astragali, excessive
30 parts suddenly of sheep, 40 parts of Radix Angelicae Sinensis, 30 parts of Radix Salviae Miltiorrhizae, 10 parts of Radix Codonopsis, 10 parts of safflower, 20 parts of Concha Ostreae, 30 parts and 10 parts of ganoderma lucidum of dandelion.
The present invention provides a kind of enema fluid for treating nephrosis, the enema fluid is using above-mentioned Chinese medicine composition as raw material, warp
Water is obtained through refining.
The present invention provides the preparation methods of above-mentioned enema fluid, include the following steps:
(1) rheum officinale, Radix Astragali, longspur epimedium, Radix Angelicae Sinensis, Radix Salviae Miltiorrhizae, Radix Codonopsis, safflower, Concha Ostreae, dandelion and ganoderma lucidum are mixed, is obtained
To mixture；
(2) add water in Xiang Suoshu mixture, 150~190 DEG C of decoctions are separated by solid-liquid separation, obtain Aqueous extracts；
(3) Aqueous extracts are mixed with ethyl alcohol, adjusts the volume final concentration of 70~85% of ethyl alcohol, precipitated impurities, mistake
Filter, obtains filtrate；
(4) ethyl alcohol in filtrate, sterilizing, the enema fluid for the nephrosis that obtains medical treatment are removed.
Preferably, each component is crushed before step (1) mixing, the partial size of the crushing is 25~50 μm.
Preferably, the ratio of amount of water and mixture is 1.7L:(0.8~1.2 in the step (2)) Kg.
Preferably, the number decocted in the step (2) is 2~4 times, and the time decocted every time is 30~60min；Every time
It is separated by solid-liquid separation after decoction, merges Aqueous extracts.
Preferably, concentration is evaporated to Aqueous extracts before step (3) mixing, Aqueous extracts are mentioned with preceding water is concentrated after concentration
The volume ratio of liquid is 1:(1.5~3).
Preferably, after the ethyl alcohol in step (4) the removal filtrate, further include the steps that (5) are diluted with water；Described
(5) in the step of being diluted with water, the filtrate volume ratio after amount of water and removal ethyl alcohol is 1.5~5:1.
The utility model has the advantages that the present invention provides a kind of compositions for treating nephrosis, enema fluid and preparation method thereof.The combination
Object includes the component of following mass parts: 5~35 parts of rheum officinale, 20~45 parts of Radix Astragali, and 20~40 parts of longspur epimedium, 20~45 parts of Radix Angelicae Sinensis,
10~35 parts of Radix Salviae Miltiorrhizae, 5~20 parts of Radix Codonopsis, 5~15 parts of safflower, 10~30 parts of Concha Ostreae, 20~40 parts of dandelion, ganoderma lucidum 5~15
Part.In the present invention, for the composition using rheum officinale as monarch drug in a prescription, logical internal organs rushes down turbid, activating microcirculation and removing stasis medicinal, and safflower, Radix Angelicae Sinensis, Radix Salviae Miltiorrhizae promoting blood circulation are supported
Blood, Radix Codonopsis, Radix Astragali, ganoderma lucidum Bu Qi Fu Zheng are let out with metaplasia qi and blood, Herba Epimedii kidney-replenishing, dandelion hardship with opening, dampness removing dissipating bind, raw dragon
Male astringency inducing prevents rheum officinale from unloading wound, is the medicine of tying-in.5 strengthening vital QI to eliminate pathogenic factors of complete square compatibility, attacks benefit dual-purpose, supports to reach QI invigorating
The effect of blood, toxin expelling drop turbid, activating microcirculation and removing stasis medicinal.Clinical treatment effective percentage is 85% or more.
Composition provided by the invention carries out on the basis of number of patent application is the patent of invention of CN201510501574.1
It improves, for improved composition to treatment of kidney disease better effect, price is more economical；Meanwhile improved composition indication
It is mutually wider compared with before-improvement, also there is good therapeutic effect to chronic glomerulonephritis.
Specific embodiment
The present invention provides a kind of Chinese medicine composition for treating nephrosis, the component including following mass parts: rheum officinale 5~35
Part, 20~45 parts of Radix Astragali, 20~40 parts of longspur epimedium, 20~45 parts of Radix Angelicae Sinensis, 10~35 parts of Radix Salviae Miltiorrhizae, 5~20 parts of Radix Codonopsis, safflower 5~
15 parts, 10~30 parts of Concha Ostreae, 20~40 parts and 5~15 parts of ganoderma lucidum of dandelion.
The composition for the treatment of nephrosis of the present invention includes rheum officinale, Radix Astragali, longspur epimedium, Radix Angelicae Sinensis, Radix Salviae Miltiorrhizae, Radix Codonopsis, safflower, life
Imperial male, dandelion and ganoderma lucidum.In the present invention, by weight, the dosage of rheum officinale is 5~35 parts to each component, preferably 20~
32 parts, more preferably 30 parts.The dosage of Radix Astragali is 20~45 parts, preferably 30~42 parts, more preferably 40 parts.The use of longspur epimedium
Amount is 20~40 parts, preferably 25~35 parts, more preferably 30 parts.The dosage of Radix Angelicae Sinensis be 20~45 parts, preferably 30~42 parts,
More preferably 40 parts.The dosage of Radix Salviae Miltiorrhizae is 10~35 parts, preferably 20~32 parts, more preferably 30 parts.The dosage of Radix Codonopsis be 5~
20 parts, preferably 8~15 parts, more preferably 10 parts.The dosage of safflower is 5~15 parts, preferably 8~12 parts, more preferably 10
Part.The dosage of Concha Ostreae is 10~30 parts, preferably 15~25 parts, more preferably 20 parts.The dosage of dandelion is 20~40 parts,
Preferably 25~35 parts, more preferably 30 parts.The dosage of ganoderma lucidum is 5~15 parts, preferably 8~12 parts, more preferably 10 parts.?
In the present invention, the Concha Ostreae is the mixture of keel and oyster, and the mixed proportion of the two is preferably 1~2:1~2, more preferably
For 1:1.The present invention is not particularly limited the source of each component, and the qualified products that this field can routinely be bought in pharmacy are equal
It can.In the present invention, rheum officinale is monarch drug in a prescription, play logical internal organs rush down it is turbid, the benefits of activating microcirculation and removing stasis medicinal；Safflower, Radix Angelicae Sinensis, Radix Salviae Miltiorrhizae blood circulation promoting nourishes blood, party
Ginseng, Radix Astragali, ganoderma lucidum Bu Qi Fu Zheng are let out with metaplasia qi and blood, Herba Epimedii kidney-replenishing, dandelion hardship with opening, dampness removing dissipating bind, and Concha Ostreae is received
Astringent method is held back, prevents rheum officinale from unloading wound, is the medicine of tying-in.Each component compatibility of the present invention has strengthening vital QI to eliminate pathogenic factors, attacks the characteristic for mending dual-purpose,
The effect of turbid nourishing qi and blood, toxin expelling drop, activating microcirculation and removing stasis medicinal can be reached.
The present invention provides a kind of enema fluids for treating nephrosis, and the enema fluid is using above-mentioned composition as raw material, Jing Shuiti
It is made.
The present invention provides the preparation methods of above-mentioned enema fluid, include the following steps:
(1) rheum officinale, Radix Astragali, longspur epimedium, Radix Angelicae Sinensis, Radix Salviae Miltiorrhizae, Radix Codonopsis, safflower, Concha Ostreae, dandelion and ganoderma lucidum are mixed, is obtained
To mixture；
(2) add water in Xiang Suoshu mixture, 150~190 DEG C of decoctions are separated by solid-liquid separation, obtain Aqueous extracts；
(3) Aqueous extracts are mixed with ethyl alcohol, adjusts the volume final concentration of 75~85% of ethyl alcohol, precipitated impurities, mistake
Filter, obtains filtrate；
(4) ethyl alcohol in filtrate, sterilizing, the enema fluid for the nephrosis that obtains medical treatment are removed.
The present invention first mixes rheum officinale, Radix Astragali, longspur epimedium, Radix Angelicae Sinensis, Radix Salviae Miltiorrhizae, Radix Codonopsis, safflower, Concha Ostreae, dandelion and ganoderma lucidum
It closes, obtains mixture.The present invention before mixing, preferably carries out pulverization process to each component, the partial size of the crushing is preferably 25
~50 μm, more preferably 30 μm.The present invention is not particularly limited the tool of the crushing and specific breaking method, this field
Conventional use of tool and method.
After obtaining mixture, the present invention adds water into mixture, and active material is extracted by way of decoction.In the present invention
In, the ratio of described plus water amount and mixture is preferably 1.7L:(0.8~1.2) Kg, more preferably 1.7L:1Kg.It is described to decoct
The temperature boiled is preferably 150~190 DEG C, and more preferably 160~180 DEG C.In the present invention, the number of the decoction is preferably 2
~4 times, more preferably 3 times.The time decocted every time is preferably 30~60min, more preferably 45min.Solid-liquid after decocting every time
Separation merges Aqueous extracts.
After obtaining Aqueous extracts, the present invention removes the impurity in Aqueous extracts by the method for alcohol precipitation.In the present invention, the alcohol
Preferably Aqueous extracts are concentrated before heavy, the volume ratio of Aqueous extracts and the preceding Aqueous extracts of concentration is preferably 1:(1.5~3 after concentration),
More preferably 1:2.Alcohol precipitation of the present invention mixes Aqueous extracts with ethyl alcohol.In the present invention, the volumetric concentration of the ethyl alcohol is excellent
It is selected as 95%.The additional amount of the ethyl alcohol is with the final concentration of standard of the volume of ethyl alcohol.The volume final concentration of the ethyl alcohol is preferably
70~85%, more preferably 80%.The Aqueous extracts and ethyl alcohol closed standing after mixing, filter after impurity precipitation, obtain
To filtrate.
After obtaining filtrate, the present invention removes the ethyl alcohol in filtrate, sterilizing, the enema fluid for the nephrosis that obtains medical treatment.The present invention is excellent
The ethyl alcohol removed in filtrate by the way of evaporation is selected, the ethyl alcohol of evaporative removal is preferably recycled, and is recycled.The present invention is being gone
After the ethyl alcohol in filtrate, the step of being diluted with water it is also preferable to include (5).In the present invention, step (5) amount of water and removal second
Filtrate volume after alcohol is than being preferably 1.5~5:1, more preferably 2:1.In the present invention, the sterilizing preferably uses gamma-rays
Method, the dosage of the sterilizing are preferably 3.0kGy.
Below with reference to embodiment to a kind of composition for treating nephrosis provided by the invention, enema fluid and preparation method thereof into
Row detailed description, but they cannot be interpreted as limiting the scope of the present invention.
Embodiment 1
Accurate weighing rheum officinale 30g, Radix Astragali 40g, Herba Epimedii 30g, Radix Angelicae Sinensis 40g, Radix Salviae Miltiorrhizae 30g, Radix Codonopsis 10g, safflower 10g, life
The male 20g of dragon, dandelion 30g, ganoderma lucidum 10g, the composition for the nephrosis that obtains medical treatment.
Embodiment 2
1) it weighs to obtain each component by dosage described in embodiment 1, each component is then crushed to 30 μm；It will be smashed big
Huang, Radix Astragali, longspur epimedium, Radix Angelicae Sinensis, Radix Salviae Miltiorrhizae, Radix Codonopsis, safflower, Concha Ostreae, dandelion and ganoderma lucidum mixing, obtain mixture；
2) after obtaining mixture, in Xiang Suoshu mixture plus water, mixture and water ratio are 1.7L:1Kg, 170 DEG C of conditions
It is lower decoct 3 times, each 45min, every time decoct after be separated by solid-liquid separation, merge Aqueous extracts soldier be concentrated rapidly, after concentration Aqueous extracts with it is dense
The volume ratio of Aqueous extracts is 1:2 before contracting.
3) Aqueous extracts are mixed with 95% ethyl alcohol after being concentrated, and adjust the volume final concentration of 80% of ethyl alcohol, are precipitated to impurity
After filter, remove ethyl alcohol therein after obtaining filtrate, sterilize, the enema fluid for the nephrosis that obtains medical treatment.
Embodiment 3
Clinical efficacy of the Chinese medicine composition of the present invention to chronic renal failure is verified in this test.
(1) data and method
(1) 86 people of case selected by is in May, 2017~2018 year May be hospitalized in Chongqing Hospital of Traditional Chinese Medicine's Nephrology it is slow
Property 3~5 phase of kidney trouble patient.Card type and syndrome integral are referring to " new Chinese medicine guideline of clinical investigations " (2002)；This
Secondary research selects case to be included in standard: Scr133-707umol/L, Ccr < 80ml/min.
Patient is randomly divided into 3 groups: blank control group 20；1 drug treatment group of embodiment 34；Conventional administration treatment group 32
Example.Wherein, conventional administration treatment group and the difference of 1 drug treatment group of embodiment be only that enema fluid to prepare raw material different (often
It is standard empirical side: Radix Astragali 30g, Radix Angelicae Sinensis 45g, Rhizoma Chuanxiong 15g, raw rhubarb that the water of enema fluid used in rule drug treatment group, which mentions raw material,
30g, raw oyster 30g, dandelion 30g, Ganoderma 15g, serissa serissoide 10g, dragon's blood 9g, radix ranunculi ternati 9g, sunset abelmoschus flower 6g).Each group
Clinical data no significant difference (P > 0.05).
(2) therapeutic scheme
Three groups are given conventional therapy: less salt, low fat, low-phosphorous, good protein diet, protein intake 0.6-0.8kg/
D controls blood pressure, corrects acid-base imbalance, anaemia, electrolyte disturbance etc..
Control group only gives conventional base treatment；1 drug treatment group of embodiment and conventional administration treatment group are in conventional therapy
On the basis of be administered bowel lavage, 3 times/week, each 200ml.Albumin excretion rate (UAER), blood lipid, fibre are checked after each group medication 8 weeks
The indexs such as fibrillarin original, serum creatinine, blood urea nitrogen, and assess patient clinical symptom.
(3) efficacy assessment standard
It is formulated referring to " guideline of clinical investigations of new Chinese medicine treatment chronic renal failure ":
1. effective: tcm clinical practice symptom, sign are obviously improved, and syndrome integral reduces >=75%；
2. effectively: tcm clinical practice symptom, sign take a favorable turn, syndrome integral reduction < 75%, >=30%；
3. invalid: tcm clinical practice symptom, sign are not improved, even aggravating, syndrome integral reduces < 30%.
(2) experimental result
(1) clinical efficacy of three groups of different disposal is counted, the results are shown in Table 1:
Clinical efficacy comparison after the treatment of 1 different disposal group of table
| Group | Number of cases | It is effective | Effectively | In vain | Total effective rate |
| 1 drug treatment group of embodiment | 34 | 17 | 13 | 4 | 88.24%* |
| Conventional administration treatment group | 32 | 12 | 13 | 7 | 78.13%* |
| Blank control group | 20 | 4 | 7 | 9 | 55% |
Compared with the control group, * P < 0.05
As can be seen from Table 1, the total effective rate and obvious effective rate of Liang Ge treatment group are all remarkably higher than control group.Embodiment 1 is given
Medicine treatment group is 88.24% to the treated effect of patients of chronic renal failure, and the treatment of conventional administration treatment group is effective
Rate is then 78.13%；The obvious effective rate of 1 drug treatment group of embodiment is 50%, and the obvious effective rate of conventional administration treatment group is
37.5%.
As can be seen that Chinese medicine composition provided by the invention is high to the treated effect of patients of chronic renal failure, aobvious
Efficiency is also higher, and compared with Empirical formula before, clinical effective rate and obvious effective rate are also significantly increased, and shows using the present invention
The Chinese medicine composition of offer has significant clinical efficacy to Patients with Chronic Kidney Disease treatment.
(2) clinical general information (urinary albumin excretion ratio UAER, blood lipid, fibrinogen, the blood pretherapy and post-treatment to patient
Creatinine SCr, blood urea nitrogen BUN) it is counted, it the results are shown in Table 2:
The detection of table 2 pretherapy and post-treatment UAER, TC, TG, FIB, SCr, BUN compare
Compared with before same group for the treatment of, * P < 0.05, * * P < 0.01；Compared with after control group treatment, #P < 0.05
After Liang Ge treatment group treatment it can be seen from the data of table 2 compared with the control group, in urinary albumin excretion ratio
(UAER), blood lipid, fibrinogen, serum creatinine (SCr), there were significant differences in blood urea nitrogen (BUN) index, and white urinating
Protein excretion rate, blood lipid etc. have significant decrease relative to conventional administration treatment group.
The comparison of adverse reaction after (3) two groups of treatments
Control group has no adverse reaction；Only there is diarrhea for 1 in 1 drug treatment group of embodiment, remaining case is different without fash, liver function
Often, the malaise symptoms such as abdominal pain, headache；There are 4 diarrhea in conventional administration treatment group, remaining has no adverse reaction.Therefore it is provided by the invention
Adverse reaction is few compared with standard empirical side for Chinese medicine composition, safer.
(3) conclusion
Before treatment, three groups of indices comparing differences are not statistically significant (P > 0.05)；After treatment, it is of the present invention in
Drug composition can be horizontal by reducing Urinary Albumin Excretion, blood lipid, fibrinogen, serum creatinine and blood urea nitrogen, protects kidney
Function, clinical efficacy are significant (P < 0.05).
Embodiment 4
Clinical efficacy of the Chinese medicine composition of the present invention to chronic glomerulus inflammation is verified in this test.
(1) data and method
Choose 82 chronic glomerulonephritis patients accepted for medical treatment Chongqing Hospital of Traditional Chinese Medicine's in May, 2017 in April, 2018, diagnosis
For standard referring to the diagnostic criteria of Nanjing China nephrology meeting the 2nd academic conference revision in 1985, card type and syndrome integral are equal
Referring to " new Chinese medicine guideline of clinical investigations " (2002)；This research selects case to be included in standard: it is small to meet chronic renal
Ball ephritis doctor trained in Western medicine and TCM syndrome diagnostic criteria；Quantity of proteinuria is 1.0-2.0g for 24 hours, hypertension continue not drop or instead on
It rises.
It is randomly divided into 3 groups: blank control group 20；1 drug treatment group of embodiment 44；With conventional administration treatment group
36.Wherein, conventional administration treatment group and the difference of 1 drug treatment group of embodiment be only that enema fluid to prepare raw material different
(it is standard empirical side that the water of enema fluid used in conventional administration treatment group, which mentions raw material: Radix Astragali 30g, Radix Angelicae Sinensis 45g, Rhizoma Chuanxiong 15g, life are big
Yellow 30g, raw oyster 30g, dandelion 30g, Ganoderma 15g, serissa serissoide 10g, dragon's blood 9g, radix ranunculi ternati 9g, sunset abelmoschus flower 6g).Respectively
Group clinical data no significant difference (P > 0.05).
(2) therapeutic scheme
Three groups take a routine treatment: sufficiently rest, control blood pressure, adjustment diet (control salinity and protein intake),
Anti-infective, isolation kidney risk factor.
Control group only gives conventional base treatment；1 drug treatment group of embodiment and conventional administration treatment group are in conventional therapy
On the basis of be administered bowel lavage, 3 times/week, each 200ml.Each group checks routine urinalysis after being administered 8 weeks, for 24 hours quantity of proteinuria, blood flesh
The indexs such as acid anhydride, blood urea nitrogen, and assess patient clinical symptom.
(3) efficacy assessment standard
Complete incidence graph: the symptoms such as patient's oedema are completely disappeared with sign, for 24 hours quantity of proteinuria persistently turn out cloudy or "+" 6 weeks with
On, or quantity of proteinuria continues < 0.2g for 24 hours, urine erythrocyte disappears under high power lens, and arena counts normal, normal renal function.
Basic to alleviate: the symptoms such as oedema disappear substantially with sign, and urine protein examination persistently reduces 50% or more, under high power lens
Urine erythrocyte no more than 3, arena are counted close to normal, normal renal function or normal (differed and are no more than with normal value
15%).
Effective: the symptoms such as oedema are clearly better with sign, and urine protein examination persistently reduces by 1 "+", or Urine proteins are fixed for 24 hours
Amount persistently reduces 25%-49%, and urine erythrocyte no more than 3 under high power lens or has improvement at normal renal function.
Invalid: clinical manifestation and above-mentioned laboratory check and are not improved or instead add severe one.
(2) experimental result
(1) clinical efficacy of three groups of different disposal is counted, the results are shown in Table 3
Clinical efficacy comparison after the treatment of 3 different disposal group of table
Compared with the control group, * P < 0.05
As can be seen from Table 3, the total effective rate and obvious effective rate of Liang Ge treatment group are all remarkably higher than control group.Embodiment 1 is given
Medicine treatment group is 90.91% to the treated effect of chronic glomerulus inflammation patient, and the treated effect of conventional administration treatment group
It is then 83.33%；The obvious effective rate of 1 drug treatment group of embodiment is 36.36%, and the obvious effective rate of conventional administration treatment group is
33.33%.
As can be seen that Chinese medicine composition provided by the invention is high to the treated effect of chronic glomerulus inflammation patient, effective
Rate is also higher, and compared with standard empirical side, clinical effective rate and obvious effective rate are also significantly increased, and shows to provide using the present invention
Chinese medicine composition to Patients with Chronic Kidney Disease treatment have significant clinical efficacy.
The comparison of adverse reaction after (2) two groups of treatments
Control group has no adverse reaction；Only there is mild diarrhea for 1 in 1 drug treatment group of embodiment, remaining case is without fash, liver
The malaise symptoms such as function exception, diarrhea, headache；There are 3 diarrhea in conventional administration treatment group, remaining has no adverse reaction.Therefore application
Adverse reaction is few for Chinese medicine composition, safer.
(3) conclusion
Patient symptom can be effectively relieved in Chinese medicine composition provided by the invention, reduce urinary protein excretion, reduce blood urine, protection
Renal function.Compared with standard empirical side, Chinese medicine composition after optimization to the clinical efficacy of Patients with Chronic Kidney Disease more.
The above is only a preferred embodiment of the present invention, it is noted that for the ordinary skill people of the art
For member, various improvements and modifications may be made without departing from the principle of the present invention, these improvements and modifications are also answered
It is considered as protection scope of the present invention.
Claims (10)
1. a kind of Chinese medicine composition for treating nephrosis, which is characterized in that the component including following mass parts: 5~35 parts of rheum officinale, yellow
20~45 parts of stilbene, 20~40 parts of longspur epimedium, 20~45 parts of Radix Angelicae Sinensis, 10~35 parts of Radix Salviae Miltiorrhizae, 5~20 parts of Radix Codonopsis, 5~15 parts of safflower,
10~30 parts of Concha Ostreae, 20~40 parts and 5~15 parts of ganoderma lucidum of dandelion.
2. Chinese medicine composition according to claim 1, which is characterized in that the component including following mass parts: rheum officinale 20~
32 parts, 30~42 parts of Radix Astragali, 25~35 parts of longspur epimedium, 30~42 parts of Radix Angelicae Sinensis, 20~32 parts of Radix Salviae Miltiorrhizae, 8~15 parts of Radix Codonopsis, safflower 8
~12 parts, 15~25 parts of Concha Ostreae, 25~35 parts and 8~12 parts of ganoderma lucidum of dandelion.
3. Chinese medicine composition according to claim 1 or 2, which is characterized in that the component including following mass parts: rheum officinale 30
Part, 40 parts of Radix Astragali, 30 parts of longspur epimedium, 40 parts of Radix Angelicae Sinensis, 30 parts of Radix Salviae Miltiorrhizae, 10 parts of Radix Codonopsis, 10 parts of safflower, 20 parts of Concha Ostreae, dandelion
30 parts and 10 parts of ganoderma lucidum.
4. a kind of enema fluid for treating nephrosis, which is characterized in that the enema fluid is in described in claims 1 to 3 any one
Drug composition is raw material, is obtained through refining through water.
5. the preparation method of enema fluid described in claim 4, which comprises the steps of:
(1) rheum officinale, Radix Astragali, longspur epimedium, Radix Angelicae Sinensis, Radix Salviae Miltiorrhizae, Radix Codonopsis, safflower, Concha Ostreae, dandelion and ganoderma lucidum are mixed, is mixed
Close object；
(2) add water in Xiang Suoshu mixture, 150~190 DEG C of decoctions are separated by solid-liquid separation, obtain Aqueous extracts；
(3) Aqueous extracts are mixed with ethyl alcohol, adjusts the volume final concentration of 70~85% of ethyl alcohol, precipitated impurities, filtering obtains
To filtrate；
(4) ethyl alcohol in filtrate, sterilizing, the enema fluid for the nephrosis that obtains medical treatment are removed.
6. preparation method according to claim 5, which is characterized in that carry out powder to each component before step (1) mixing
Broken, the partial size of the crushing is 25~50 μm.
7. preparation method according to claim 5, which is characterized in that the ratio of amount of water and mixture in the step (2)
Example is 1.7L:(0.8~1.2) Kg.
8. the preparation method according to claim 5 or 7, which is characterized in that the number decocted in the step (2) is 2~4
Secondary, the time decocted every time is 30~60min；It is separated by solid-liquid separation after decocting every time, merges Aqueous extracts.
9. preparation method according to claim 8, which is characterized in that steamed before step (3) mixing to Aqueous extracts
Hair concentration, the volume ratio of Aqueous extracts and the preceding Aqueous extracts of concentration is 1:(1.5~3 after concentration).
10. preparation method according to claim 9, which is characterized in that after the ethyl alcohol in step (4) the removal filtrate,
Further include the steps that (5) are diluted with water；Filtrate body in the step of (5) are diluted with water, after amount of water and removal ethyl alcohol
Product is than being 1.5~5:1.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201910044647.7A CN109432182A (en) | 2019-01-17 | 2019-01-17 | A kind of Chinese medicine composition that treating nephrosis, enema fluid and preparation method thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201910044647.7A CN109432182A (en) | 2019-01-17 | 2019-01-17 | A kind of Chinese medicine composition that treating nephrosis, enema fluid and preparation method thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN109432182A true CN109432182A (en) | 2019-03-08 |
Family
ID=65544156
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201910044647.7A Withdrawn CN109432182A (en) | 2019-01-17 | 2019-01-17 | A kind of Chinese medicine composition that treating nephrosis, enema fluid and preparation method thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN109432182A (en) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN111067941A (en) * | 2019-11-14 | 2020-04-28 | 重庆市中医院 | Traditional Chinese medicine suppository for treating chronic renal failure |
-
2019
- 2019-01-17 CN CN201910044647.7A patent/CN109432182A/en not_active Withdrawn
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN111067941A (en) * | 2019-11-14 | 2020-04-28 | 重庆市中医院 | Traditional Chinese medicine suppository for treating chronic renal failure |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN102100872A (en) | Chinese medicine preparation for treating mastitis | |
| CN110420303A (en) | A kind of Chinese medicine preparation of the promoting flow of qi and blood circulation and its application | |
| CN109432182A (en) | A kind of Chinese medicine composition that treating nephrosis, enema fluid and preparation method thereof | |
| CN104225319A (en) | Traditional Chinese preparation for treating acute renal failure | |
| CN102872336B (en) | Traditional Chinese medicine for treating multiple myeloma | |
| CN1052889C (en) | Chinese proprietary for curing hepatitis | |
| CN104888121B (en) | Chinese medical extract of auxiliary treatment pelvic infecton and its preparation method and application and profit body frost | |
| CN105902888A (en) | Traditional Chinese medicine decoction for treating infantile acute nephritis | |
| CN103386101B (en) | Traditional Chinese medicine preparation for nonspecific cystitis treatment and preparation method thereof | |
| CN104288579A (en) | Traditional Chinese medicine for treating chronic nephritis and preparation method thereof | |
| CN105327171A (en) | Traditional Chinese medicine electuary for treating mastitis and preparing method thereof | |
| CN105561004A (en) | Traditional Chinese medicine composition for preventing and treating chronic nephritis | |
| CN105343518A (en) | Traditional Chinese medicine formula for treating chronic aplastic anemia and preparation method thereof | |
| CN104873777A (en) | Traditional Chinese medicine composition for treating hepatitis and preparing method of traditional Chinese medicine composition | |
| CN104800729A (en) | Decoction capable of nourishing kidney, promoting recovery, and eliminating albuminuria | |
| CN103599187A (en) | Chinese herbal medicine for treating mastitis of dairy cow and nanometer injection preparation method of Chinese herbal medicine | |
| CN111375036B (en) | Traditional Chinese medicine composition for treating novel coronavirus pneumonia and application thereof | |
| CN108567926B (en) | Traditional Chinese medicine composition for treating blood stasis collateral blocking type autoimmune hepatitis and preparation method thereof | |
| CN106389670A (en) | Application of Guiqi blood-enriching oral liquid in prevention and treatment of AIDS | |
| CN107224453A (en) | A kind of Chinese medicine composition and its application method for treating membranous nephropathy | |
| CN105853768A (en) | Traditional Chinese medicine formula for treating rheumatoid arthritis and preparing method and application thereof | |
| CN105641131A (en) | Traditional Chinese medicine for treating acute appendicitis | |
| CN104623387A (en) | Pharmaceutical composition for treating chronic nephritis | |
| CN104435554B (en) | Treat the Chinese medicine composition of hepatitis B | |
| CN104784596A (en) | Traditional Chinese medicine for treating ankylosing spondylitis |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| WW01 | Invention patent application withdrawn after publication | ||
| WW01 | Invention patent application withdrawn after publication |
Application publication date: 20190308 |